Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Microbot Medical announces CEO Harel Gadot's upcoming interview on Benzinga All Access on December 10, 2024, at 10:50am ET. The discussion will focus on the company's LIBERTY® Endovascular Robotic System and the growing surgical robotics market.
The company has submitted an FDA 510(k) application for the LIBERTY® system, which is the world's first single-use, fully disposable endovascular robotic system. The technology eliminates the need for expensive capital equipment while offering benefits such as reduced radiation exposure for medical staff, improved ergonomics, potential cost savings, increased procedure efficiency, and enhanced quality of care.
Microbot Medical annuncia l'imminente intervista del CEO Harel Gadot su Benzinga All Access il 10 dicembre 2024, alle 10:50 ET. La discussione si concentrerà sul Sistema Robotico Endovascolare LIBERTY® dell'azienda e sul crescente mercato della robotica chirurgica.
L'azienda ha presentato una domanda di FDA 510(k) per il sistema LIBERTY®, che è il primo sistema robotico endovascolare monouso e completamente usa e getta al mondo. Questa tecnologia elimina la necessità di costosi equipaggiamenti e offre vantaggi come una ridotta esposizione alle radiazioni per il personale medico, un'ergonomia migliorata, potenziali risparmi sui costi, maggiore efficienza nelle procedure e una qualità delle cure migliorata.
Microbot Medical anuncia la próxima entrevista con el CEO Harel Gadot en Benzinga All Access el 10 de diciembre de 2024, a las 10:50 am ET. La discusión se centrará en el Sistema Robótico Endovascular LIBERTY® de la compañía y en el creciente mercado de la robótica quirúrgica.
La compañía ha enviado una solicitud de FDA 510(k) para el sistema LIBERTY®, que es el primer sistema robótico endovascular desechable y de un solo uso en el mundo. Esta tecnología elimina la necesidad de costosos equipos de capital y ofrece beneficios como la reducción de la exposición a la radiación para el personal médico, mejor ergonomía, ahorros de costos potenciales, mayor eficiencia en los procedimientos y una mejor calidad de atención.
Microbot Medical는 CEO Harel Gadot의 인터뷰가 Benzinga All Access에서 2024년 12월 10일 오전 10:50 ET에 예정되어 있다고 발표했습니다. 이번 논의는 회사의 LIBERTY® 혈관 내 로봇 시스템과 성장하는 수술 로봇 시장에 초점을 맞출 것입니다.
회사는 LIBERTY® 시스템에 대한 FDA 510(k) 신청서를 제출했습니다. 이는 세계 최초의 일회용 완전 소모성 혈관 내 로봇 시스템입니다. 이 기술은 비싼 자본 장비의 필요성을 없애고, 의료 직원의 방사선 노출 감소, 개선된 인체 공학, 잠재적인 비용 절감, 절차 효율성 향상 및 치료의 질 향상과 같은 이점을 제공합니다.
Microbot Medical annonce la prochaine interview du PDG Harel Gadot dans Benzinga All Access le 10 décembre 2024 à 10h50 ET. La discussion se concentrera sur le Système Robotique Endovasculaire LIBERTY® de l'entreprise et le marché croissant de la robotique chirurgicale.
L'entreprise a soumis une demande de FDA 510(k) pour le système LIBERTY®, qui est le premier système robotique endovasculaire jetable et à usage unique au monde. Cette technologie élimine le besoin d'équipements coûteux tout en offrant des avantages tels qu'une exposition réduite aux radiations pour le personnel médical, une meilleure ergonomie, des économies potentielles, une efficacité accrue des procédures et une qualité des soins améliorée.
Microbot Medical kündigt das bevorstehende Interview mit CEO Harel Gadot bei Benzinga All Access am 10. Dezember 2024 um 10:50 Uhr ET an. Die Diskussion wird sich auf das LIBERTY® Endovaskuläre Robotersystem des Unternehmens und den wachsenden Markt für chirurgische Robotik konzentrieren.
Das Unternehmen hat einen FDA 510(k) Antrag für das LIBERTY® System eingereicht, das weltweit das erste Einmal- und vollständig entsorgbare endovaskuläre Robotersystem ist. Diese Technologie beseitigt die Notwendigkeit teurer Investitionsgüter und bietet Vorteile wie reduzierte Strahlenbelastung für das medizinische Personal, verbesserte Ergonomie, potenzielle Kosteneinsparungen, höhere Effizienz der Verfahren und verbesserte Versorgungsqualität.
- FDA 510(k) submission completed for LIBERTY® Endovascular Robotic System
- Innovative single-use disposable design eliminates need for expensive capital equipment
- Technology offers potential for reduced healthcare costs and improved procedure efficiency
- Product not yet FDA approved
- Commercialization timeline uncertain pending regulatory review
Insights
This upcoming interview on Benzinga All Access represents a routine corporate communication event rather than market-moving news. While the CEO will discuss the LIBERTY® system and the company's vision, such promotional interviews typically don't materially impact stock performance. The more significant news was actually mentioned in passing - the FDA 510(k) submission, but that appears to have been announced separately and would warrant its own analysis.
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:50am ET on December 10, 2024. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss Microbot Medical’s LIBERTY system, the continued growth and adoption of surgical robotics, and how the Company plans to redefine the peripheral endovascular space with LIBERTY®.
Earlier today, the Company announced that it has submitted the FDA 510(k) for commercialization of the LIBERTY® Endovascular Robotic System.
As the world’s first single-use, fully disposable endovascular robotic system, LIBERTY® eliminates the need for large and expensive capital equipment and streamlines customers’ access to robotics. With its remote control, LIBERTY® is designed to significantly reduce radiation exposure to physicians and staff, and improve ergonomics, which has the potential to reduce the physical strain on healthcare providers. The Company also believes that LIBERTY® has the potential to lower procedure costs, increase procedure efficiency and improve the overall quality of care.
About Microbot Medical®
Microbot Medical® Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical® Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic Surgical System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic Surgical System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
What is the status of Microbot Medical's (MBOT) FDA application for the LIBERTY system?
What are the key features of Microbot Medical's (MBOT) LIBERTY robotic system?
When is Microbot Medical's (MBOT) CEO appearing on Benzinga All Access?
